The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study

The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study

Background: In Japan, only two medications of immediate-release levodopa with distinct ratios of decarboxylase inhibitor (DCI), namely levodopa/benserazide 100/25 mg and levodopa/carbidopa 100/10 mg, are available for the treatment of Parkinson's disease (PD). The relationship between the diffe...

Full description

Bibliographic Details
Main Authors:	Baba, Y. (Author), Futamura, A. (Author), Kinno, R. (Author), Nabeshima, Y. (Author), Nomoto, S. (Author), Osakabe, Y. (Author), Shoji, D. (Author), Takahashi, S. (Author), Yasumoto, T. (Author)
Format:	Article
Language:	English
Published:	Elsevier B.V. 2022
Subjects:	Benserazide Carbidopa Levodopa Motor complications Parkinson's disease
Online Access:	View Fulltext in Publisher

Similar Items

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats
by: Masoud Alirezaei
Published: (2015-10-01)

Hepatoprotective Effects of Betaine Against Oxidative Stress Induced by Levodopa and Benserazide in Rats
by: M Alirezaei, et al.
Published: (2015-02-01)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
by: Bigman DY, et al.
Published: (2018-04-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

Benserazide-induced diarrhea – A retrospective clinical study
by: Ilona Csoti, et al.
Published: (2021-01-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
by: Luminita Celia POPA, et al.
Published: (2020-06-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
by: Wen-Wen Wang, et al.
Published: (2019-06-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Clinical effect of levodopa and benserazide hydrochloride tables combined with visual occlusion for amblyopia in children
by: Li-Bing Yi, et al.
Published: (2018-11-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
by: D. Santos-García, et al.
Published: (2021-03-01)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016-01-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

EFFICACY, SAFETY AND PATIENT’S QUALITY OF LIFE OF LONG-TERM TREATMENT WITH LEVODOPA-CARBIDOPA INTESTINAL GEL IN ADVANCED PARKINSON’S DISEASE IN ROMANIA: RESULTS FROM GLORIA OBSERVATIONAL STUDY
by: Jozsef SZASZ, et al.
Published: (2020-03-01)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
by: Constantin VA, et al.
Published: (2020-07-01)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
by: József Attila Szász, et al.
Published: (2021-06-01)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
by: Daniël van Poppelen, et al.
Published: (2021-06-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01)

Dopaminergic agents: back to the basics – a small review
by: Neha Sharma, et al.
Published: (2017-12-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
by: Sten-Magnus Aquilonius, et al.
Published: (2017-04-01)

Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiao Dong Liu, et al.
Published: (2019-08-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
by: Walaa A. Kamel, et al.
Published: (2020-09-01)

Lo Nuevo ante la Enfermedad de Parkinson
by: Juan Mendoza Vega
Published: (1990-12-01)

Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein
by: Aki Shimozawa, et al.
Published: (2019-06-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
by: Szász JA, et al.
Published: (2019-11-01)

The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists
by: Huayun Deng, et al.
Published: (2013-04-01)

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “off” Episodes: A Comprehensive Review
by: Amnon A. Berger, et al.
Published: (2020-12-01)

Exploring Parkinson’s disease: A question and answer-based approach
by: Philippe Rizek, et al.
Published: (2018-01-01)

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
by: Benedicta Obenewaa Dankyi, MPhil, et al.
Published: (2020-01-01)